share_log

Demystifying Insmed: Insights From 7 Analyst Reviews

インスメッドの謎を解く:7人のアナリストレビューからの洞察

Benzinga ·  2024/11/22 07:00

Throughout the last three months, 7 analysts have evaluated Insmed (NASDAQ:INSM), offering a diverse set of opinions from bullish to bearish.

The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.

BullishSomewhat BullishIndifferentSomewhat BearishBearish
Total Ratings52000
Last 30D01000
1M Ago20000
2M Ago21000
3M Ago10000

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $89.71, a high estimate of $105.00, and a low estimate of $74.00. This upward trend is evident, with the current average reflecting a 5.54% increase from the previous average price target of $85.00.

bigjpg

Investigating Analyst Ratings: An Elaborate Study

A clear picture of Insmed's perception among...

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする